



## **ViroGates announces the clinical implementation of suPARnostic® Quick Triage at hospitals in Region Zealand to be conducted by the clinical immunology department at Næstved Hospital**

24.3.2020 11:53:20 CET | ViroGates | Company Announcement

No. 5-2020

24 March 2020

**BIRKERØD, DENMARK** - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces today that Region Zealand will implement suPARnostic® Quick Triage. Initially the test will be used to help triage patients admitted to the hospital with suspicion of COVID-19 disease. The analyses will initially be conducted at Næstved Hospital's clinical immunology department. The remaining six hospitals in the region will have samples transported for analysis at Næstved Hospital on a daily basis.

ViroGates has previously offered free test kits to hospitals in Denmark to test potential COVID-19 patients. The company remains committed to combating COVID-19 and will initially supply free test kits to Næstved Hospital for this purpose.

The implementation is not restricted to the COVID-19 situation but will be offered as a general analysis to the hospitals in the region. The hospitals in the region are Næstved, Slagelse, Ringsted, Holbæk, Køge, Roskilde and Nykøbing Sj. The total number of beds is 1677 (excluding psychiatric wards). Acute care services are offered at the hospitals in Køge, Slagelse and Nykøbing Sj.

Following the initial implementation, ViroGates and other hospitals in the region will evaluate the need for additional analysis capacity to be implemented locally at the other hospitals in the region.

**CEO Jakob Knudsen, says in a comment:** *"At ViroGates, we are proud to help during these difficult times for our hospital system. There is no doubt that the COVID-19 situation forces overburdened healthcare professionals to make even faster triage decisions. We are confident that suPAR measurements can help identify low-risk COVID-19 patients for discharge and high-risk COVID-19 patients for admission and are pleased that Region Zealand has made an accelerated decision to implement suPARnostic® Quick Triage to help in this important task to combat the COVID-19 outbreak. Initially, we will supply our products free of charge as our contribution to combating the pandemic. We are, however, also pleased to note that the regional hospitals will use our products beyond the COVID-19 crisis in their work to assess the overall inflammatory disease status and risk of their patients."*

**Medical Director Region Zealand Ph.D. Keld M. Homburg says:** *"The suPARnostic® Quick Triage will now be available for all departments within hospitals in Region Zealand, Denmark. The Department of Clinical Immunology offers the analysis, having brought forward the implementation due to the extraordinary COVID-19 pandemic. The aim is to fulfill clinical requirements to include the analysis in the evaluation of patients submitted with this disease. Moreover, the suPARnostic® Quick Triage will be available for all patients within the regional hospitals whatever the diagnostic purpose. Thus, the implementation also allows patients suffering from rheumatic diseases to be assessed using suPARnostic® Quick Triage testing."*

### **For further information please contact:**

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: [jk@virogates.com](mailto:jk@virogates.com)

*Region Zealand*

Keld M. Homburg, Medical director, Ph.D.

Clinical Immunology

Zealand University Hospital

*Certified Advisor:*

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: [per.lonn@vhcorp.se](mailto:per.lonn@vhcorp.se)

## **About ViroGates**

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit [www.virogates.com](http://www.virogates.com).

## **About suPAR and suPARnostic®**

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Siemens ADVIA XPT instruments and Roche Diagnostics' cobas instruments. ViroGates works with partners to develop solutions for other platforms.

## **Disclaimer**

*Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.*

## **Contacts**

- Jakob Knudsen, CEO, +45 2226 1355, [jk@virogates.com](mailto:jk@virogates.com)

## **Attachments**

- [20200324-ViroGates company announcement 5.pdf](#)